Abstract：
Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor. This case highlights the unique nature of spiradenocarcinomas as well as the potential benefit of targeted therapy.
摘要：
螺旋腺癌是罕见的恶性皮肤附件肿瘤。我们描述了一个新的病例，患有侵袭性CDKN2A突变的螺旋腺癌，对CDK4/6抑制剂有反应。该病例突出了螺旋腺癌的独特性质以及靶向治疗的潜在益处。
